SCHEMBL6019580

SCHEMBL6019580

Cc1ccc(I)c2cccnc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HSP90AA1 P07900 3/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
NPC1 O15118 2/20 0.52
HTT P42858 5/20 0.52
SLC6A2 P23975 3/20 0.52
PSMD14 O00487 2/20 0.52
COPS5 Q92905 2/20 0.52
LMNA P02545 3/20 0.50
USP2 O75604 3/20 0.50
KDM4E B2RXH2 3/20 0.50
MAPK1 P28482 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
ALDH1A1 P00352 2/20 0.50
TP53 P04637 2/20 0.50
HPGD P15428 2/20 0.50
ALOX15 P16050 2/20 0.50
HIF1A Q16665 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18848335 0.84 HTR1A (0.56) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL18757318 0.84 HTT (0.61) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL18840389 0.83 HSP90AA1 (0.57) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL812451 0.83 HTT (0.70) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL2056205 0.76 KDM4E (0.61) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL21130214 0.76 PSMD14 (0.72) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL2002972 0.76 HTT (0.72) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL113423 0.76 KDM4E (0.61) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL12332383 0.76 MEN1 (0.53) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1
SCHEMBL2557719 0.76 L3MBTL1 (0.61) MEN1KMT2ASMN1; SMN2HSP90AA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11818932-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-14 US disclosed
US-20230320981-A1 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS INTERVET INC. (US) 2023-10-12 US disclosed
US-11712416-B2 Solid oral pharmaceutical compositions for isoxazoline compounds INTERVET INC. (US) 2023-08-01 US disclosed
US-11690289-B2 Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-27 US disclosed
WO-2023280177-A1 SMALL MOLECULE COMPOUND TARGETING BCL9/β-CATENIN INTERACTION 南通聚太生物科技有限公司 2023-01-12 WO disclosed
US-11329230-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2022-05-10 US disclosed
US-11179372-B2 Isoxazoline solution containing vitamin E for use with sanitized drinking water INTERVET INC. (US) 2021-11-23 US disclosed
US-11165024-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2021-11-02 US disclosed
US-20210320154-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2021-10-14 US disclosed
US-20210167296-A1 ORGANIC COMPOUND CONTAINING HETEROCYCLIC RING AND HAVING LOW LUMO PROPERTIES, AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME SOLUS ADVANCED MATERIALS CO., LTD. (KR) 2021-06-03 US disclosed
US-20170179204-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2017-06-22 US disclosed
US-20170179401-A1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2017-06-22 US disclosed
US-20170105972-A1 SOFT CHEWABLE PHARMACEUTICAL PRODUCTS INTERVET, INC. (US) 2017-04-20 US disclosed
US-20170012221-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2017-01-12 US disclosed
WO-2011114099-A1 PURIFICATION TAGS OF SYNTHETIC PEPTIDES AND PROTEINS ALMAC SCIENCES (SCOTLAND) LIMITED (GB) 2011-09-22 WO disclosed
US-7098215-B2 Nitrogenous compounds and antiviral drugs containing the same KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 2006-08-29 US disclosed
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound KUREHA CORPORATION (JP) 2004-08-12 US disclosed
US-20040092556-A1 Nitrogenous compounds and antiviral drugs containing the same KUREHA CORPORATION (JP) 2004-05-13 US disclosed
EP-1389460-A1 CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND Kureha Chemical Industry Co., Ltd. (JP) 2004-02-18 EP disclosed
EP-1273571-A1 NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME Kureha Chemical Industry Co., Ltd. (JP) 2003-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092556-A1 Nitrogenous compounds and antiviral drugs containing the same NSUN2, ZC3HAV1L, PNP MEN1 3048/4885KMT2A 3470/4885SMN1; SMN2 2044/4885
US-11329230-B2 Organic light-emitting device EML4, SUN2, TRPA1 MEN1 2816/4885KMT2A 1971/4885SMN1; SMN2 4133/4885
US-11179372-B2 Isoxazoline solution containing vitamin E for use with sanitized drinking water PROC, EPX, CYP27B1 MEN1 4113/4885KMT2A 2957/4885SMN1; SMN2 3282/4885
US-11690289-B2 Organic compound containing heterocyclic ring and having low lumo properties, and organic electroluminescent device using the same LEF1, PPOX, LIMK1 MEN1 1500/4885KMT2A 1677/4885SMN1; SMN2 3103/4885
US-20170012221-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES EPCAM, SLC39A3, L1CAM MEN1 1788/4885KMT2A 2473/4885SMN1; SMN2 4287/4885
US-20170105972-A1 SOFT CHEWABLE PHARMACEUTICAL PRODUCTS PAM, TAS2R46, TAS2R16 MEN1 442/4885KMT2A 838/4885SMN1; SMN2 510/4885
US-11712416-B2 Solid oral pharmaceutical compositions for isoxazoline compounds CYP3A7, SI, CYP2A7 MEN1 4505/4885KMT2A 2112/4885SMN1; SMN2 899/4885
US-20230320981-A1 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS CYP3A7, SI, CYP2A7 MEN1 4505/4885KMT2A 2112/4885SMN1; SMN2 899/4885
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound CXCR4, CXCR1, CXCR2 MEN1 2191/4885KMT2A 4302/4885SMN1; SMN2 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.